Finance

Lists
Why is EBS down 3.68%?
Dive Deeper
EBS:NYSE
Emergent Biosolutions Inc
$6.81
-3.68%
(-0.26) 1D
$6.88
+1.03% (+0.070)
After hours
Closed: Oct 8, 4:00:09 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EBS...
Open
$7.01
High
$7.01
Low
$6.78
Mkt. cap
349.17M
Avg. vol.
1.18M
Volume
1.15M
52-wk high
$14.06
52-wk low
$4.36
EPS
-$3.51
Beta
2.28
Shares outstanding
51.27M
No. of employees
900
Open
$7.01
High
$7.01
Low
$6.78
Mkt. cap
349.17M
Avg. vol.
1.18M
Volume
1.15M
52-wk high
$14.06
52-wk low
$4.36
EPS
-$3.51
Beta
2.28
Shares outstanding
51.27M
No. of employees
900
News stories
From web sources and news partners
Profile
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
About Emergent Biosolutions Inc
CEORobert G. Kramer Sr. | Joseph C. Papa
Employees900
FoundedSep 5, 1998
HeadquartersRockville, Maryland, United States
SectorBiotechnology
Websiteemergentbiosolutions.com
Analyst ratings
Based on 2 analysts giving stock ratings to EBS in the past 3 months
Hold
Buy
1
Hold
0
Sell
1
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for EBS in the last 3 months.
Highest
Current $6.81
$10.00 (+46.84%)
Average
$10.00 (+46.84%)
Lowest
$10.00 (+46.84%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$10.00
+46.8%
09/09/2026
Jessica Fye
J.P. Morgan
Sell
Initiated
-
-
08/21/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.60 / $0.11
+445.45%beat
Revenue / Est. (USD)
234.30M / 177.50M
+32.00%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
231.10M
148.70M
156.10M
234.30M
Cost of goods sold
99.00M
94.00M
82.40M
106.10M
Cost of revenue
99.00M
94.00M
82.40M
106.10M
Research and development expenses
200.00K
-600.00K
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
28.30M
61.60M
46.60M
44.60M
Operating expense
44.80M
77.30M
63.10M
61.80M
Total operating expenses
143.80M
171.30M
145.50M
167.90M
Operating income
87.30M
-22.60M
10.60M
66.40M
Other non operating income
-3.70M
-8.10M
13.90M
-
EBT including unusual items
57.60M
-50.70M
13.40M
-166.30M
EBT excluding unusual items
68.40M
-45.40M
13.50M
56.40M
Income tax expense
6.40M
3.90M
6.60M
13.90M
Effective tax rate
11.11%
-7.69%
49.25%
-8.36%
Other operating expenses
-
-
-
-
Net income
51.20M
-54.60M
6.80M
-180.20M
Net profit margin
22.15%
-36.72%
4.36%
-76.91%
Earnings per share
1.06
-0.43
0.21
0.60
Interest and investment income
-
-
-
-
Interest expense
-15.20M
-14.70M
-11.00M
-10.00M
Net interest expenses
-15.20M
-14.70M
-11.00M
-10.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
110.30M
2.40M
33.50M
89.90M
Gain or loss from assets sale
2.20M
-11.20M
800.00K
11.90M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps